Surgeries & Interventions

Adena Health Pauses Cardiac Surgeries Amid Mounting Controversies

Ohio’s Adena Health System has temporarily stopped performing heart surgeries, after months of growing scrutiny and some troubling deaths.

Adena Health reportedly “parted ways with” two of its cardiac surgeons, and will transfer all scheduled heart surgeries to OSU Wexner Medical Center during its “pause.” 

  • However, Adena’s cardiology, and thoracic and vascular surgery operations were not affected, and the system will continue to operate its cath lab and treat all incoming emergent heart attacks.  

Adena’s cardiac surgery pause and surgeon departures follow the recent deaths of two women during coronary artery bypass grafting (CABG) procedures, although problems within Adena’s cardiac surgery department have been mounting for some time.

  • Just a few weeks ago one of the surgeons was accused of “propping up” another deceased patient to look “fake alive” and then urging family members to remove her from life support
  • Two of the surgeons were allegedly seen watching YouTube videos to prepare for medical procedures they were unfamiliar with, including one procedure that turned fatal and another that led to three follow up procedures
  • In May, another Adena cardiac surgeon was accused by 31 sources of performing at least three TAVR procedures without proper credentials, including one where the patient died

The two surgeons both left after less than two years working at Adena Health, while the third apparently remains with the medical center.

Given that Adena is Southern Ohio’s top medical center, the problems with its cardiac surgery department became widely covered by local news outlets.

  • However, news of the “propped up” woman earned international headlines and apparently inspired an upcoming People Magazine story, while these latest deaths during CABG procedures prompted Adena Health to take action.

The Takeaway

Cardiac surgery deaths happen at even the best run hospitals, but Adena’s growing list of controversies and the fact that it elected to pause all heart surgeries is a clear sign that there was something seriously wrong there. Let’s hope Adena figures out what’s wrong and fixes these issues before restarting its cardiac surgery operations.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiovascular Disease August 4, 2025

The Impact of Physical Activity Before and After CV Events August 4, 2025

A long-term analysis of the CARDIA study revealed that moderate-to-vigorous physical activity steadily declines from young adulthood through midlife, but patients destined to develop cardiovascular disease experience rapid activity decreases more than a decade before their first event. Collecting data over 37 years, researchers tracked ~3k participants from young adulthood to middle age and paired […]

Cardiology Pharmaceuticals July 31, 2025

AstraZeneca’s Anselamimab Comes Up Short in Phase 3 Trial July 31, 2025

In a setback to one of its rarer disease pipelines, AstraZeneca’s amyloidosis antibody, anselamimab, failed to significantly reduce all-cause mortality and CV hospitalizations in the CARES Phase 3 trial’s overall patient population.  The CARES clinical program was the largest prospective cardiac AL amyloidosis investigation to date, enrolling 406 patients to test whether anselamimab could reduce […]

Cardiology Pharmaceuticals July 28, 2025

SGLT2i Prescriptions Increase for HF, With Some Exceptions July 28, 2025

Three years after SGLT2 inhibitors were added to the heart failure treatment guidelines, a JAMA Cardiology study reveals significant new prescriptions, with a few key patient sub-groups falling behind. Researchers analyzed prescribing patterns of SGLT2 inhibitors for 760k HF patients in the National Cardiovascular Data Registry and found significant and rapid uptake in the last […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!